Personalised medicine for nonsmall cell lung cancer

被引：34
|
作者：
Mascaux, Celine [1 ,2 ]
Tomasini, Pascale [1 ,2 ]
Greillier, Laurent [1 ,2 ]
Barlesi, Fabrice [1 ,2 ]
机构：
[1] Aix Marseille Univ, AP HM, Multidisciplinary Oncol & Therapeut Innovat Dept, Marseille, France
[2] Aix Marseille Univ, Inserm U911 CRO2, Marseille, France
来源：
EUROPEAN RESPIRATORY REVIEW | 2017年 / 26卷 / 146期
关键词：
PHASE-III TRIAL; CISPLATIN PLUS GEMCITABINE; OPEN-LABEL; 1ST-LINE TREATMENT; DOUBLE-BLIND; PD-L1; IMMUNOHISTOCHEMISTRY; MAINTENANCE THERAPY; MET AMPLIFICATION; AMERICAN-SOCIETY; PEMETREXED PLUS;
D O I：
10.1183/16000617.0066-2017
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
After years of standard care prescribed to cancer patients without any selection except the primary site and histology of the tumour, the era of precision medicine has revolutionised cancer care. Personalised medicine refers to the selection of patients for specific treatment based on the presence of specific biomarkers which indicate sensitivity to corresponding targeted therapies and/or lower toxicity risk, such that patients will have the greatest chance of deriving benefit from the treatments. Here, we review personalised medicine for nonsmall cell lung cancer.
引用
收藏
页数：13
相关论文
共 50 条
  • [31] PROGNOSTIC FACTORS IN NONSMALL CELL LUNG-CANCER
    FELD, R
    BORGES, M
    GINER, V
    GINSBERG, R
    HARPER, P
    KLASTERSKY, J
    LACQUET, L
    PAESMANS, M
    PAYNE, D
    ROSELL, R
    SAUSE, W
    SCULIER, JP
    SHAW, E
    SORENSEN, JB
    SPLINTER, T
    STAHEL, R
    BUNN, P
    LUNG CANCER, 1994, 11 : S19 - S23
  • [32] Surgical Treatment of Metachronous Nonsmall Cell Lung Cancer
    Haraguchi, Shuji
    Koizumi, Kiyoshi
    Hirata, Tomomi
    Hirai, Kyoji
    Mikami, Iwao
    Kubokura, Hirotoshi
    Nakajima, Yuki
    Shimizu, Kazuo
    ANNALS OF THORACIC AND CARDIOVASCULAR SURGERY, 2010, 16 (05) : 319 - 325
  • [33] The Role of Proteasome Inhibition in Nonsmall Cell Lung Cancer
    Escobar, Mauricio
    Velez, Michel
    Belalcazar, Astrid
    Santos, Edgardo S.
    Raez, Luis E.
    JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, 2011,
  • [34] Controversies in Mediastinal Staging for Nonsmall Cell Lung Cancer
    Ashok, Apurva
    Jiwnani, Sabita S.
    Karimundackal, George
    Bhaskar, Maheema
    Shetty, Nitin S.
    Tiwari, Virendra Kumar
    Niyogi, Devayani M.
    Pramesh, C. S.
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2021, 42 (05) : 406 - 414
  • [35] PALLIATIVE CHEMOTHERAPY FOR NONSMALL CELL LUNG-CANCER
    ADELSTEIN, DJ
    SEMINARS IN ONCOLOGY, 1995, 22 (02) : 35 - 39
  • [36] Chemotherapy in elderly patients with nonsmall cell lung cancer
    Veluswamy, Rajwanth R.
    Levy, Benjamin
    Wisnivesky, Juan P.
    CURRENT OPINION IN PULMONARY MEDICINE, 2016, 22 (04) : 336 - 343
  • [37] Update in PET imaging of nonsmall cell lung cancer
    Rohren, EM
    Lowe, VJ
    SEMINARS IN NUCLEAR MEDICINE, 2004, 34 (02) : 134 - 153
  • [38] SHOULD NONSMALL CELL-CARCINOMA OF THE LUNG BE TREATED WITH CHEMOTHERAPY - PRO - CHEMOTHERAPY IS FOR NONSMALL CELL LUNG-CANCER
    MASTERS, GA
    VOKES, EE
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1995, 151 (05) : 1285 - 1287
  • [39] Preoperative staging for advanced nonsmall cell lung cancer
    Fukuse, T
    Wada, H
    Tanaka, F
    Yanagihara, H
    Hirata, T
    Hitomi, S
    XXX WORLD CONGRESS OF THE INTERNATIONAL COLLEGE OF SURGEONS, VOLS 1-2, 1996, : 957 - 960
  • [40] INTRAOPERATIVE BRACHYTHERAPY IN NONSMALL CELL LUNG-CANCER
    NORI, D
    SEMINARS IN SURGICAL ONCOLOGY, 1993, 9 (02): : 99 - 107
12345